Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norethindrone enanthate is a synthetic progestogen (progestin) of the 19-nortestosterone group used primarily as a long-acting injectable contraceptive for women. It acts as an agonist of the progesterone receptor, suppressing ovulation and altering cervical mucus and endometrial lining to prevent pregnancy. Norethindrone enanthate is the C17β enanthate ester of norethisterone (norethindrone), making it a derivative of testosterone with modifications that enhance its progestogenic activity and duration. It was first introduced by Schering in 1957 under the brand name Noristerat and was notable as the first progestogen-only injectable contraceptive[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethindrone enanthate.